HER2-Positive Colorectal Cancer: Novel Approaches

A panel of expert oncologists consider the role of HER2 expression in colorectal cancer and review novel targeted therapies in this setting.

EP. 1: Colorectal Cancer: Prevalence, Workup, and Molecular Subtypes

April 7th 2023

Opening their discussion on colorectal cancer, expert panelists consider its growing prevalence and highlight key molecular subtypes.

EP. 2: Colorectal Cancer: An Overview on Molecular Profiling

April 7th 2023

Shared insight on appropriate molecular lab testing options that should be explored following a diagnosis of colorectal cancer.

EP. 3: Role of HER2 Expression in Colorectal Cancer

April 14th 2023

A brief review of HER2 amplification and how it may impact the treatment pathway for patients with a diagnosis of colorectal cancer.

EP. 4: Role of Circulating Tumor DNA Testing in Colorectal Cancer

April 14th 2023

In the context of colorectal cancer clinical trials, panelists reflect on the role of liquid biopsies to help inform treatment decisionmaking.

EP. 5: Treatment Algorithm for Metastatic Colorectal Cancer

April 21st 2023

Broadening their conversation, expert oncologists define the treatment algorithm for patients diagnosed with colorectal cancer.

EP. 6: HER2-Amplified Colorectal Cancer: Clinical Trial Data

April 21st 2023

A focused discussion on HER2-amplified colorectal cancer and respective clinical trials that inform use of targeted agents in this setting.

EP. 7: Real-World Use of HER2-Directed Therapies in Colorectal Cancers

April 28th 2023

Expert perspectives on the real-world use of HER2-directed therapies in patients with HER2-amplified colorectal cancer.

EP. 8: Evolutions in the HER2-Amplified CRC Treatment Landscape

April 28th 2023

Looking toward the future management of HER2-amplified colorectal cancer, panelists reflect on ongoing clinical trials and evolving treatment strategies.

EP. 9: Audience Q&A: Best Practices in Managing HER2-Amplified CRC

May 5th 2023

Fielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.